Symbiotic.blue, a newly launched UK techbio venture, is developing a next-generation artificial intelligence-driven drug discovery (AIDD) platform. By enhancing generative AI with neuroscience-inspired methodologies, the company aims to create smarter, multi-targeted therapeutics to tackle complex diseases, beginning with obesity.
Founded by a team of seasoned life sciences entrepreneurs and world-renowned academics from the Universities of Oxford and Cambridge, Symbiotic.blue is currently raising a pre-seed round to build its proprietary platform and initiate early-stage discovery programs.
Company Details
- Industry
- Health And Human Services
- NAICS
-
Administration of Human Resource ProgramsAdministration of Veterans' Affairs
- Website
- https://symbiotic.blue
- Keywords
- Artificial Intelligence (AI), Machine Learning (ML), Drug Discovery, Bioinformatics, Computational Biology, Chemoinformatics, Deep Learning, Molecular Modeling, Target Identification, Biomarker Discovery, Structure-Based Drug Design (SBDD), High-Throughput Screening (HTS), Omics Data Analysis (Genomics, Proteomics), Translational Medicine, Precision Medicine, Data Science, Healthcare AI, Pharmaceutical, TechBio, Biotech, lifesciences, obesity, GLP-1.
Symbiotic.blue Questions
Symbiotic.Blue's website is https://symbiotic.blue
Symbiotic.Blue's LinkedIn profile is https://www.linkedin.com/company/symbiotic-blue
Symbiotic.Blue's industry is
Health and Human Services
Symbiotic.Blue's top competitors are
Snp Therapeutics,
Create Therapeutics,
Mykynd,
Curamir Therapeutics, Inc.,
Argo Therapeutics Gmbh,
Hydro Auto-Energies Ltd.,
Art The Science,
Six Therapeutics Inc.,
Glyconics Ltd,
Desna Therapeutics.
Symbiotic.Blue's categories are Health and Human Services
